Eli Lilly’s (LLY) CFO to Participate in Goldman Sachs Health Conference

Eli Lilly and Co. (LLY) has announced that its chief financial officer (CFO) will participate in the upcoming Goldman Sachs (GS) Global Health Care Conference.

Eli Lilly CFO Lucas Montarce will be featured in a fireside chat at the conference at 8 a.m. on June 10. A live audio webcast will be available on Eli Lilly’s investor website, and a replay of the presentation will remain on the site for 90 days after the event.

It’s not clear what will be discussed during the fireside chat, but there is certainly lots to discuss, from Eli Lilly’s ongoing battle with rival Novo Nordisk (NVO) for weight loss drug supremacy, to U.S. President Donald Trump’s pledge to lower prescription drug costs for Americans, and looming tariffs on pharmaceutical imports.

Leading Conference

Goldman Sachs’ Global Health Care Conference is an annual event that is now in its 46th year. The event brings together leading experts in the health care space to discuss a number of issues impacting the industry, including medical trends, medication breakthroughs, and investment opportunities.

As one of America’s leading drug makers, Eli Lilly typically has a large presence at the conference. CFO Lucas Montarce’s participation in a fireside chat comes as interest grows in Eli Lilly’s development of a pill version of its popular Zepbound weight loss medication, which is working its way through regulatory approvals.

Is LLY Stock a Buy?

The stock of Eli Lilly has a consensus Strong Buy recommendation among 19 Wall Street analysts. That rating is based on 17 Buy, one Hold, and one Sell recommendations issued in the last 12 months. The average LLY price target of $1,003.60 implies 33.23% upside from current levels.

Read more analyst ratings on LLY stock